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The first lineage differentiation of cells during pre-implantation embryo development is 
critical for continued embryonic growth.  Though several transcription factors (TFs) have 
been identified that are involved in this transition, a specific mechanism of regulation has 
yet to be determined.  Previous studies in our laboratory have shown the TF Lef1 is 
involved in differentiation of mouse embryonic stem cells into trophoblastic stem cells 
through the Wnt signaling pathway.  Lef1 is known to be involved in lineage 
determination of adult skin stem cells.  As we observed that two isoforms of Lef1 were 
expressed at different stages of pre-implantation development, we hypothesized that Lef1 
was interacting with the other well-established lineage differentiation TFs, Nanog, Oct4, 
and Cdx2, in these early embryos.  At the blastocyst stage, no significant changes in 
mRNA expression were seen when siRNAs, specifically designed to knockdown Lef1 
expression, were injected in early embryos; however, knockdown of Lef1 did not 
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Chapter 1: Literature Review 
Early Embryo Development 
  Early in mammalian development, the cells of the embryo are able to become 
any one of the many different cell types found in the body.  However, just before 
blastocyst formation, in a process known as compaction, the cells of the embryo 
compress causing the blastomeres to flatten and form tight junctions between the 
cells.  It is at this stage when the cell population begins to differentiate into two 
different cell types signifying the formation of a blastocyst (Figure 1).  The single 
layer of multipotent cells surrounding the perimeter of the embryo have an epithelial-
like morphology and are referred to as trophectoderm (TE) cells (Ralston and 
Rossant, 2005).  These trophoblast cells later become the fetal portion of the placenta.  
Fluid enters into the embryo forming an open cavity, which is referred to as the 
blastocoel.  The other cell type found at this time in the early embryo is a pluripotent 
collection of inner cells, known as the inner cell mass (ICM); these cells are the 
predecessors for all cells types of the embryo proper.  At the late blastocyst stage a 
second differentiation occurs in which the ICM further separates into the epiblast and 
primitive endoderm.  Multipotent primitive endoderm cells then migrate to cover the 
blastocoelic surface.  These cells later become the visceral and parietal yolk sac, 
structures that provide nutrients and patterning information for the developing 
embryo.  The other emerging cell type at this time is the epiblast.  Epiblastic cells can 
be found between the TE and the primitive endoderm; and it is these cells that form 
the three germ layers of the embryo; endoderm, mesoderm, and ectoderm.  It is 
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imperative that these two differentiation processes are seamless as both cell lineages 





Figure 1: Pre-implantation mammalian embryo development 
 
 
(Ralston and Rossant, 2005) 
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Once these cell types are established and the blastocyst hatches from the 
protective zona pellucida, implantation occurs in mammals.  The trophoblastic cells 
mature to from the placenta; an organ that aids in gas and nutrient exchange as well as 
in waste elimination.  In some mammalian species, implantation occurs relatively 
quickly.  In mice, once the embryo hatches from the zona pellucida, implantation 
occurs.  However in other mammals, particularly ruminants, there is a delayed 
implantation during which the extensive structures of the placenta and uterus develop 
(Guillomot, 1995).  Unlike humans and mice where the embryonic cells invade the 
uterine lining, ruminants form structures on both the maternal and embryonic surfaces 
that interlock to allow exchange of nutrients (Guillomot, 1995; Lee and DeMayo, 
2004).  In cows and ewes, where the tube-like uterus must support the growth of a 
relatively large fetus, there is an extended elongation period during which the embryo 
stretches to approximately 150 mm long before attaching.  Therefore, the ruminant 
trophoblastic cells must be able to proliferate and remodel the cellular shape without 
fully differentiating (Wintenberger-Torrés and Fléchon, 1974).  In ruminants and 
other species in which implantation is delayed, the integrity of the trophoblast cells is 
critical; the embryo must rely on these cells for nutrients (Wintenberger-Torrés and 
Fléchon, 1974).  Without the precise balance of TE and ICM in the first 
differentiation step, implantation would fail.   
 
Transcription Factors 
Initial work with mouse carcinoma cell lines showed that altering the 
expression of certain factors could change the lineage identity of cells.  This led some 
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researchers to believe that there are proteins or other factors involved in maintaining 
pluripotency.  These factors, known as transcription factors, are directly associated 
with DNA and either enhance or repress transcription of genes.  Then in the 1980s, 
embryonic stem cells (ES) were derived from the ICM of mouse blastocysts.  These 
cells provided a better system in which to study early developmental transcription 
factors (Evans and Kaufman, 1981; Martin, 1981).  Current research to determine 
which transcription factors are involved in the establishment and ability to sustain 
pluripotency has largely been based on work with mouse embryos or embryonic stem 
cell lines because those cell lines have been well characterized and fully validated.  It 
has been difficult to determine the molecular components and pathways utilized in 
early differentiation because they are part of a complex network of proteins that are 
involved in self-regulation and regulation of other factors and pathways.  Several 
transcription factors such as Oct4, Nanog, and Cdx2 have been recognized as key 




Figure 2: Known transcription factors involved in early embryo development 
 




Oct4, also known as Oct3/4 or Pou5f1, is a POU-domain (Pit-Oct-Unc) 
transcription factor encoded by the Pou5f1 gene.  Common among all POU family 
members, Oct4 recognizes the sequence ATGCAAAT and turns on genes that contain 
an octamer motif in the promoter.  Early studies showed Oct4 being expressed in 
germ cells and early embryos, which made Oct4 a leading candidate for establishing 
or maintaining pluripotency of cells (Nichols et al., 1998; Schöler et al., 1990; 
Schöler et al., 1989).  Initially, it was considered a master regulator for the 
maintenance of pluripotency (Pesce and Scholer, 2001).  Since then many researchers 
have studied Oct4 to determine its role in early embryos and stem cells.  In mice, 
Oct4 can initially be found in all cells of the early embryo, but after compaction it is 
isolated to ICM; the site where pluripotent cells originate (Pan et al., 2006; Pan et al., 
2002; Pesce and Scholer, 2001; Ralston and Rossant, 2005).   In bovine, goat, and 
porcine blastocysts, however, Oct4 can be found in both the ICM and TE cells 
(Degrelle et al., 2005; He et al., 2006; Kirchhof et al., 2000).  Oct4 is expressed in 
both cell types of bovine blastocysts until approximately day 10, but by day 12 Oct4 
is downregulated in both the ICM and TE cells (van Eijk et al., 1999).  It is important 
to point out that though Oct4 is highly conserved in mammalian species, the pattern 
of expression is not the same in murine and bovine early embryos.   
 
In murine embryos missing the Oct4 gene, implantation does not occur and 
the inner cells of the blastocysts look more like trophectoderm cells (Nichols et al., 
1998; Niwa et al., 2000).  Also, no ICM markers are expressed, and stem cells can not 
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be cultured from the embryos (Rossant, 2001).  These findings identified Oct4 as a 
necessary factor for proper early development.  Because the ICM of embryos missing 
Oct4 had a trophectoderm-like morphology, this led to the idea that the 
trophectoderm lineage is a default pathway for early embryonic cells and a 
pluripotent factor like Oct4 would be needed to overcome a TE fate.   
 
Studies were conducted that tried to define the specific mechanism by which 
Oct4 maintained pluripotency.  Although Oct4 is predominately found in pluripotent 
and germ-line cells,  constitutive expression of Oct4 in ES cells was not enough to 
prevent the cells from differentiating (Niwa et al., 2000; Pesce and Scholer, 2001). 
This finding seemed to dispel the thought of Oct4 as the sole factor involved in 
maintaining cell pluripotency.  Furthermore, overexpression of Oct4 in mouse stem 
cell lines led to differentiation into extraembryonic endoderm (Niwa et al., 2000).  
When the murine Oct4 promoter was attached to an enhanced green fluorescent 
protein and transfected into early bovine and porcine embryos, all preimplantation 
stages of both species expressed GFP (Kirchhof et al., 2000).  This study indicated 
that the Oct4 promoter regulation was conserved across several mammalian species.  
The variation of Oct4 expression seen in these species was more likely an adaptation 
because of differences in peri-implantation timing, rather than alteration of the 
transcription factor function.   
 
Subsequent studies using reporter assays and small interfering RNA (siRNA) 
showed that Oct4 worked in concert with Cdx2 to establish specific lineages (Hay et 
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al., 2004; Niwa et al., 2005).  When Cdx2 was induced, Oct4 was no longer able to 
function correctly to maintain pluripotency (Niwa et al., 2005).  When Oct4 
expression was knocked down using siRNA there was an increase in Cdx2 expression 
(Hay et al., 2004).  Because Cdx2 and Oct4 do not appear to be directly competing to 
bind DNA, it was proposed that either the two proteins interacted through an 
autoregulatrory element or they were in close proximity to one another when bound 
to DNA (Niwa et al., 2005).  These studies bring to light that not only is the presence 
or absence of these factors important, but the concentration at which they are present 
must be considered.  Niwa suggested there was a threshold of Oct4 that was needed 
for cells to maintain pluripotent characteristics, but if an excess of Oct4 accumulated 
the cells would differentiate (Niwa et al., 2000; Niwa et al., 2005).  To maintain a 
steady expression of Oct4, it is likely that this transcription factor acts as its own 
repressor to decrease production when too much protein is being made (Pan et al., 
2006).   
 
Nanog 
 One important regulator of Oct4 may be the Nanog protein.  Nanog, coined 
from legendary land of Tír na nÓg meaning land of forever young, was first 
characterized in 2003 and was given its name because it was found to be involved in 
establishing and maintaining pluripotency in embryonic cells (Chambers et al., 2003; 
Mitsui et al., 2003).  This homeobox protein was found using digital differential 
display and though the sequence was similar to other homeobox family members, the 
amino acid sequence was noticeably different making Nanog very unique (Matsui and 
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Okamura, 2005; Mitsui et al., 2003).  Nanog is not expressed until the morula stage in 
mouse embryos, and is generally found in the ICM of blastocysts, in early germ cells, 
and embryonic stem (ES) cells (Cavaleri and Scholer, 2003; Chambers et al., 2003; 
Matsui and Okamura, 2005; Mitsui et al., 2003).  In bovine spherical blastocysts, 
Nanog was restricted to the ICM tissues, but as the embryo elongated Nanog could be 
found in both embryonic and extra-embryonic tissues (Degrelle et al., 2005).   
 
When first discovered, Nanog was considered a repressor of trophectoderm 
lineage by inhibiting genes involved in signaling the cell to differentiate (Chambers et 
al., 2003; Mitsui et al., 2003).  However, later it was found that Nanog contains two 
strong trans-activation domains at the C-terminus end dispelling the notion that 
Nanog acts only as a repressor (Pan et al., 2006; Pan et al., 2002).  In mice, it has 
been shown that both Nanog and Oct4 work together to maintain the undifferentiated 
cellular population of the ICM (Ralston and Rossant, 2005).  Then as lineage 
determination progresses, Nanog is involved in maintaining pluripotency of the inner 
cells of the ICM.  These cells are the precursors for the formation of the epiblast, and 
cells not expressing Nanog differentiate into primitive endoderm (Chambers et al., 
2003).   
 
To accurately understand the mechanisms by which Nanog is affecting cells, 
ablation and overexpression experiments were completed.  In mutant mouse ES cell 
lines in which the Nanog gene was removed, the cells still expressed ES cell specific 
markers.  These cells were also able to grow on a layer of STO feeder cells, but the 
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growth was very slow (Mitsui et al., 2003).  When the Nanog gene was removed from 
mouse embryos, the Nanog mutant was morphologically indistinguishable from 
normal embryos at 3.5 dpc, but Nanog deficient embryos did not survived (Mitsui et 
al., 2003).  The ICM from these Nanog deficient embryos was dissected out and 
plated onto culture dishes.  The cultured cells presented a primitive endoderm-like 
morphology (Cavaleri and Scholer, 2003; Mitsui et al., 2003; Ralston and Rossant, 
2005).  When Nanog was overexpressed in mouse ES cells, there was no longer a 
need to supplement the medium with the cytokine LIF (Cavaleri and Scholer, 2003; 
Chambers et al., 2003; Mitsui et al., 2003).  Previously, mouse ES cells required the 
addition of LIF to maintain pluripotent characteristics. Though Nanog may not be 
explicitly needed for initial formation of blastocysts, it does appear to be necessary 
for the establishment of the epiblast and, therefore, the three germ layers of the fetus.     
 
Both Oct4 and Nanog have been shown to be important factors involved in 
establishing and maintaining pluripotency in their own right, but it is clear neither 
works alone.  There is an Oct4 binding site 181 base pairs upstream of the Nanog 
promoter which suggests Nanog may be a target of Oct4 (Pan et al., 2006).  This 
finding helped explain why overexpression of Oct4 led to an endoderm lineage rather 
than maintenance of pluripotency.  Mouse ES cells that overexpressed Oct4 or cells 
with reduced Nanog expression looked very similar (Pan et al., 2006).  When Nanog 
was expressed below baseline levels, Oct4 activated the Nanog promoter to increase 
expression, but when Nanog levels were high Oct4 worked as a repressor (Pan et al., 
2006).  These studies further indicated that many transcription factors associated with 
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pluripotency are not regulated in an on/off manner but rather through a more complex 
network.  The expression of these transcription factors is stimulated or repressed 
based on the concentration of other factors present.  Both Nanog and Oct4 appear to 




Nanog and Oct4 have been established as markers of pluripotency and of the 
ICM, but what about TE cells?  Caudal-type homeobox transcription factor 2, or 
Cdx2, is one of a few transcription factors found specifically in the outer 
trophectodermal (TE) cells and is, therefore, commonly used as a trophectoderm 
specific marker.  Cdx2 mRNA is first expressed at the eight-cell stage; and by the 
early morula, Cdx2 can be seen in the nucleus and cytoplasm of the outer 
presumptive trophectoderm cells (Beck et al., 1995).  In bovine embryos, Cdx2 was 
restricted to the TE at the ovoid and filamentous blastocyst stages (Degrelle et al., 
2005).   
     
Cdx2 has been implicated in lineage restriction of the pluripotency factors, 
Oct4 and Nanog (Strumpf et al., 2005).  It was suggested by Pesce and Scholer in 
2001, that the TE lineage is a default cellular pathway rather than one that is triggered 
by specific events or factors because TE cells form when Oct4 is removed (Pesce and 
Scholer, 2001).  However, in embryos in which Cdx2 has been removed the 
trophectodermal cells display morphology inconsistent with that of normal cells. 
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Without Cdx2, TE integrity and function are lost and the future stem cell population 
is distorted (Chawengsaksophak et al., 1997; Strumpf et al., 2005).  In the Cdx2 
mutants, Oct4 and Nanog were expressed at normal level in the perimeter cells of the 
embryo (Strumpf et al., 2005).  These findings enforced the idea that Cdx2 may be 
needed to override the signal that maintains pluripotency in ICM cells and push the 
outer embryonic cells into another lineage.  Cdx2 may specify the TE fate of the outer 
cells by blocking or decreasing the expression of Oct4 and Nanog.  Another group 
showed that adding Cdx2 to ES cells was sufficient to push the cells into a 
trophectoderm-like morphology.  However, if Oct4 expression had already begun to 
decrease, Cdx2 was not required (Niwa et al., 2005).  At this time, the mechanism by 
which Nanog and Oct4 are segregated to the inner cells while Cdx2 is exclusively 
expressed in the outer cells is unclear. Presumably there are other upstream factors 
being activated through context-dependent receptor pathways that can recognize the 
surrounding environment, which starts a cascade of events orchestrating these events.       
 
Wnt Pathway 
The Wnt signaling pathway is an established network of proteins that has 
recently been shown to be involved in mouse ES cell differentiation (Ogawaa et al., 
2006; Pilon et al., 2006; Reya and Clevers, 2005).  Also, several Wnt ligands, 
including Wnt3a, are expressed in early mouse preimplantation embryos (Lloyd et al., 
2003).  Receptors for the Wnt pathway send signals down the canonical pathway for 
cell fate determination and to the noncanonical pathway for tissue polarity control and 
cellular movement (Katoh and Katoh, 2007).  The canonical Wnt pathway was the 
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first to be characterized, and it acts through a specific set of proteins that are highly 
conserved across many different species.  This pathway has been linked with cellular 
behavior, proliferation, and even apoptosis through the regulation of target genes 
(Moon et al., 2001).  Both the canonical and noncanonical Wnt signaling pathways 
are transduced through Frizzled family receptors, but only the canonical pathway 
utilizes the protein β-catenin.  Without a Wnt signal, β-catenin is phosphorylated in 
the cytoplasm of cells and degraded.  With β-catenin degraded, the transcription 
factors Tcf and Groucho act together to stop the expression of Wnt specific target 
genes.  After the Wnt signal binds to its cell surface receptor, β-catenin is 
dephosphorylated allowing it to accrue in the cytoplasm and enter into the nucleus.  
In the nucleus β-catenin has access to the genome and replaces Groucho to form a 
complex with Lef/Tcf, allowing these factors to work as transcriptional activators 
(Gordon and Nusse, 2006; Reya and Clevers, 2005).  It is possible that cell surface 
receptors stimulate the Wnt pathway and its target genes in response to neighboring 
cell signals to either maintain pluripotency or allow differentiation in mouse ES cells 
and early embryos.  Since the Tcf/Lef1 family is a component of the canonical Wnt 
pathway, it is likely that one or more of these family members is involved.  In mouse 
ES cells it was recently shown that Tcf3, transcription factor 3, interacts with the 
Nanog promoter through a Groucho binding domain to decrease Nanog expression.  
This interaction appears to be regulating the expression of Nanog and allowing 
lineage commitment of the cells (Pereira et al., 2006).  Another member of the 
Tcf/Lef1 family, Lef1, has been associated with adult stem cells, and it also contains 




 Lymphoid enhancer-binding factor 1 (Lef1) was first identified from 
lymphoid-specific cDNA clones in 1991, and was found to contain a sequence-
specific DNA-binding domain known as an HMG (High Mobility Group) box (Travis 
et al., 1991).  HMG boxes have the unique ability to bind in the minor grove of DNA.  
Once bound an amino acid side chain is inserted between two base pairs causing the 
DNA to bend.  This allows other proteins to aggregate together to either activate or 
repress surrounding genes.  Early studies showed that Lef1 was expressed during 
murine embryogenesis (Oosterwegel et al., 1993), but it wasn’t until 1996, with the 
aid of yeast two-hybrid screens, that Lef1 was recognized as part of the Wnt pathway.   
 
Lef1 mRNA is alternatively spliced, and different isoforms are expressed in 
early development.  In mouse 8-cell embryos the full-length Lef1 is expressed, but 
after compaction of the morula and development into the blastocyst another form of 
Lef1 lacking the sixth exon, (Lef1∆6), is expressed (He, unpublished).  Though the β-
catenin biding site and the HMG DNA domain are still present, the Groucho binding 
domain is missing in this isoform.   
 
In mouse ES cells Lef1∆6 was the dominant isoform expressed, but overexpression 
did not seem to affect Nanog (He, unpublished).  However, mouse ES cells induced 
to express increased levels of Lef1∆6, by removal of LIF, responded to the cytokine 
Wnt3a with an increase of Cdx2 expression.  When these cells were grown in TS 
(trophoblast stem) cell medium they differentiated into trophoblast-like cells (He, 
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unpublished).  It may be that the different Lef1 isoforms allow Lef1 and other family 
members to be involved in both Nanog regulation and TE differentiation in a context 
dependent manner.  Lef1 has been found to be involved in differentiation of 
multipotent skin stem cells (Merrill et al., 2001).  These studies point to Lef1 as a 
player in the lineage specification of cells.   
 
Knock down of Lef1 using siRNA 
 Removing Lef1 from early embryos and mouse ES cells should shed some 
light onto the molecular context that Lef1 plays in early development.  Previously a 
Lef1 “knockout” would be created that removed the gene of interest utilizing 
homologous recombination.  This approach, the former gold standard for disrupting 
the mouse genome, is lengthy and expensive, especially in bovids were the gestation 
period is longer and embryonic stem cells have not been established.  Also, many 
genes involved in early differentiation are difficult to knockout because they are 
needed to create a viable embryo (Nichols et al., 1998; Strumpf et al., 2005).  Instead, 
RNA interference (RNAi) can be used in early embryos as mRNA degradation and, 
therefore, protein expression can be specifically targeted at a particular stage.  
 
RNAi is mediated through post-transcriptional sequence specific gene 
silencing.  Double-stranded RNA with a homologous sequence to the gene that is to 
be silenced, is first cleaved into short strands of 21-22 base pairs long utilizing an 
enzyme known as Dicer (Bernstein et al., 2001; Elbashir et al., 2001b; Hamilton and 
Baulcombe, 1999; Hammond, 2005).  These short double-stranded RNA pieces are 
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known as small interfering RNAs (siRNA).  Both strands of the siRNA combine with 
a conglomerate of proteins known as an RNA-induced silencing complex (RISC) 
(Rana, 2007).  The antisense portion of the siRNA guides the RISC to its 
complementary RNA sequence in the cytoplasm where the mRNA is cleaved, 
preventing the protein from being made.  Before RNAi was introduced in 1998 (Fire 
et al., 1998), single-stranded antisense and sense RNA were used, which did not 
provide consistent gene silencing. 
 
 Not only did RNAi provide an easier more specific mode of gene silencing, 
but the machinery was also found to be conserved across many other species 
including mammals (Elbashir et al., 2001a; Kennerdell and Carthew, 1998; Svoboda 
et al., 2000; Wargelius et al., 1999; Wianny and Zernicka-Goetz, 2000).  The first 
attempts at mammalian gene silencing using double stranded RNA (dsRNA) were 
completed in mouse oocytes in 2000 (Svoboda et al., 2000; Wianny and Zernicka-
Goetz, 2000).  Two independent groups were able to knock down genes by 
microinjection of dsRNA into oocytes, and resulting embryos were comparable to 
knockout mouse embryos.  dsRNA and siRNA were also used to knock down specific 
mRNA expression in mammalian cell lines.  In some cell types, siRNA can be added 
directly to the culture media of cells and the molecules can cross cellular membranes 
unaided, however, in most cases lipid complexes such as Lipofectamine™ must be 




Because embryos are surrounded by a zona pellucida, different approaches are 
needed to transfer siRNA molecules into the cytoplasm.  Currently three main 
techniques have been used to transfect siRNA into embryos: electroporation, 
microinjection, and direct incubation.  Electroporation uses electricity to create small 
holes in the cellular membranes allowing the small RNA molecules to enter the cell 
(Calegari et al., 2002; Tompers and Labosky, 2004).  Microinjection uses 
micromanipulation tools to puncture the zona pellucida of the embryo and inject 
siRNA into specific cells.  Microinjection is a common technique used in embryo 
manipulation because it is a controlled method of getting specific amounts of 
materials into an embryo (Jaffe and Terasaki, 2004).  The third technique uses a 
higher concentration of siRNA added directly into the embryo culture media.  At a 
higher concentration, this complex is able to penetrate into a cell or embryo without 
the use of electroporation or direct injection (Kawamura et al., 2003; Kigami et al., 
2003; Sandy et al., 2005).  Since handling of embryos can affect developmental 
progress, the direct incubation of embryos in siRNA offers a way to transfect without 
an added manipulation step.  Another approach gaining popularity is to transfect the 
embryo with short hairpin RNA which when transduced produces the siRNA needed 
for silencing of gene expression.    
 
The use of RNAi in mammalian embryos opens up an efficient way to study 
transcription factors that have been identified as important players in differentiation.  
Gestational losses due to malformed TE are a major contributor to inefficiencies 
observed in advanced reproductive technologies.   Knowledge about how the 
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trophectoderm emerges may lead to a better understanding of how early embryo 
manipulation alters the potential for the embryo, especially in its ability to implant 
into the uterus.  Also, understanding what triggers cells to differentiate during early 




Chapter 2: Methods 
Embryo culture 
Bovine embryos were purchased from a commercial company (Bomed, 
Madison, WI).  Embryos used for determining expression pattern of key transcription 
factors were shipped as fertilized zygotes and were harvested at 2-cell, 4-8 cell, 
morula, and blastocyst stages.  The number of embryos collected from each stage can 
be found in Appendix Table 1.   
 
Bovine oocytes used for siRNA microinjections were also shipped from 
Bomed.  Frozen-thawed Jersey bull semen was spun at 7,000 x G in 10 mL PBS 
containing magnesium and calcium supplemented with 10 mg/mL BSA and 
penicillin-streptomycin.  Sperm were incubated for 15 minutes in Tyrode's Albumin-
Lactate-Pyruvate (TALP) containing 4.5 U of heparin and then diluted in 11 mL of 
TALP-FM solution.  500 µL of diluted sperm and 10-25 oocytes were placed in 4-
well IVF culture plates (Falcon) at a final concentration of around 2 x 106 sperm 
cells/mL for approximately 20 hours.  All presumptive zygotes were cultured in vitro 
in sequential G1/G2 medium at 38.5°C in 5% CO2, 5% O2 and 90% N2.   
 
Murine embryos were purchased from Embryotech Laboratories Inc. 
(Wilmington, MA) as cryogenically frozen 1-cell embryos.  Straws of embryos were 
thawed according to manufacture’s protocol.  After injections, embryos were cultured 





Bovine fetal fibroblasts were obtained from the USDA (Beltsville, MD) and 
cultured in a basic feeder medium containing DMEM (Dulbecco’s Modified Eagle’s 
Medium; Gibco, Carlsbad, CA) supplemented with 10% FBS, and 2 mM L-
glutamine. 
 
R1 mouse ES cells (ATCC SCRC-1011) were grown in ES medium on 0.1% 
gelatin-coated plates in the absence of feeder cells.  The ES medium was comprised 
of DMEM (Gibco, Carlsbad, CA) supplemented with 15% FBS (Fetal bovine serum), 
2 mM L-glutamine,  1x non-essential amino acids,  0.1 mM β-mercaptoethanol, and 
1000 U/ml LIF (Leukemia Inhibitory Factor) (Chemicon, Billerica, MA) to prevent 
differentiation.   
 
Murine and bovine siRNA sequences 
Stealth small interfering RNA (siRNA) oligos (Invitrogen, Carlsbad, CA) 
were designed using the BLOCK-iT RNAi Designer from Invitrogen and Tuchl 
guidelines (Elbashir et al., 2002).  The annealed duplexes were prepared as 
recommended by the manufacturer.  The murine sense strand was determined based 
on the Lef1 gene starting from the 136 base of Lef1 open reading frame (ORF)  
(NM_010703) and was as follows: 5'- GGCGACUUAGCCGACAUCAAGUCAU-3’ 
and the antisense strand was 5’-AUGACUUGAUGUCGGCUAAGUCGCC -3'.  The 
bovine Lef1 siRNA oligos were designed against the predicted Lef1 sequence starting 
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from the 139 base of Lef1 ORF.  The sense strand used to target the bovine Lef1 gene 
was 5’-GAAGGUGACUUAGCCGACAUCAAGU-3’ and the antisense strand was 
5’-ACUUGAUGUCGGCUAAGUCACCUUC-3’.   
 
Transfection of cells with Lef1 siRNA 
To validate the effect of Lef1 siRNA on knockdown of Lef1 mRNA, both 
mouse ES cells and bovine fibroblasts were transiently transfected with StealthTM 
Lef1 siRNA or a scrambled, StealthTM missense siRNA.  All cell transfections were 
one of three treatment groups: Lef1 siRNA used to knock down expression of Lef1, 
missense siRNA used as a transfection control to identify off-target effects from 
transfection procedure, or a control treatment in which no siRNA was added to the 
cells.    
 
The bovine fetal fibroblasts were plated in 24-well plates (2x105/well) in 
triplicate for each treatment.  This experimental design was replicated on three 
different days.  After cells were 70% confluent 5 pmol of missense or Lef1 stealth 
RNAi (80 nM) and 2 µL Lipofectamine 2000 were randomly added to each 
designated treatment well.  siRNA complexes were prepared in Opti-MEM 
(Invitrogen, Carlsbad, CA) according to manufacturer’s guidelines and Lipofectamine 
2000 (Invitrogen, Carlsbad, CA) was used to enhance siRNA uptake.  The third 
treatment type, designated as control, was not transfected with siRNA or 
Lipofectamine; instead equivalent amounts of Opti-MEM, the media used to dilute 
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the siRNA, were added to the wells.  After 24 hours, cells were collected in lysis 
buffer and flash frozen in liquid nitrogen for a later recovery of RNA. 
 
Mouse ES cells were transfected in duplicate for each treatment, and the 
experimental design was replicated on three different days.  ES cells were trypsinized 
and plated into 24-well gelatin-coated culture plates in 400 µL of ES medium.  To 
each well, 100 µL of one of the three treatments was added.  For RNAi transfection, 
ES cells (1x105/well) were transfected with complexes consisting of 5 pmol Lef1 or 
missense stealth siRNA (80 nM) and 2 µl Lipofectamine 2000 mixed in Opti-MEM 
(Invitrogen, Carlsbad, CA).  Only Opti-MEM was added to cells designated as 
control.  Cells were cultured for 24 hours.  After this period, the cells were collected 
in lysis buffer and flash frozen in liquid nitrogen for a later recovery of RNA. 
 
Microinjection of Lef1 siRNA into embryos 
Both murine and bovine zygotes were randomly sorted into one of three 
groups: control in which the oocytes were not injected, missense siRNA in which the 
oocytes were injected with a scrambled missense siRNA sequence to identify 
detrimental effects from the siRNA injection procedure, or Lef1 siRNA to knock 
down expression of Lef1.  Embryo manipulation plates were prepared using Optilux 
(BD Biosciences, Franklin Lakes, NJ) culture dishes with a 150 µL drop of the 
handling media EmCare (ICPbio, Auckland, New Zealand) overlaid with mineral oil 
(Sigma, St.Louis, MO).  Small groups of 10 embryos were placed into the injection 
drop and microinjections were completed on an inverted microscope (Leica DMIRB).  
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For bovine embryo injections, 40 µM of siRNA was mixed with 10 mg/mL of 40,000 
MW neutral Texas red-conjugated dextran (TRD) diluted in saline (Invitrogen, 
Carslsbad, CA) in a 1:1 ratio giving a final concentration of 20 µM of siRNA.  For 
murine embryos 20 µM of siRNA and TRD were mixed in a 3:1 ratio for final 
concentration of 15 µM.  5 µL of siRNA-TRD mixture, missense siRNA or Lef1 
siRNA, was loaded into a Femtotips II injection needle purchased from Eppendorf 
(Eppendorf, Hamburg, Germany) and attached to a FemtoJet (Eppendorf, Hamburg, 
Germany).  A volume of approximately 10-20 pmols of dsRNA was injected into the 
cytoplasm of the embryos.  After injections, bovine embryos were placed into G1 
culture media and mouse embryos into KSOM.   
 
Bovine and murine 4-8 cell embryos from each treatment were placed in a 
lysis buffer and immediately flash frozen in liquid nitrogen.  Number of bovine and 
murine embryos collected can be found in Appendix Table 2 and Appendix Table 3 
respectively.  Remaining bovine embryos were observed seven days after 
insemination to determine blastocyst rates and morphology.  Four days after being 
thawed, murine embryos were checked for morphology and blastocyst rates.  All 
blastocysts of a treatment group were collected in lysis buffer and flash frozen in 
liquid nitrogen.  The number of murine blastocysts collected from each treatment 




RT-PCR and qRT-PCR 
Total RNA was extracted from embryos using an Absolutely RNA Nanoprep 
Kit (Stratagene, La Jolla, CA).  The RNA was then quantified at the Center for 
Advanced Research in Biotechnology (CARB, Rockville, MD) using an Agilent 2100 
bioanalyzer.  An aliquot of RNA (8 ng) was reverse transcribed into cDNAs using 
SuperScript III (Invitrogen, Carlsbad, CA).   
 
Total RNA from murine and bovine cells was extracted using an Absolutely 
RNA Miniprep Kit (Stratagene, La Jolla, CA).  RNA from these cells was quantified 
using a Quant-iT RiboGreen RNA Assay Kit (Invitrogen, Carlsbad, CA).  For both 
cell types, an aliquot of RNA (60 ng) was reverse transcribed into cDNA by means of 
SuperScript III.   
 
Equivalent amounts of cDNA were used as templates for Reverse 
transcription PCR (RT-PCR), and Platinum Taq (Invitrogen, Carlsbad, CA) was used 
as the DNA polymerase.  Primer sequences used are shown in Appendix Table 5.  
The PCR thermocycling conditions were the following: an initial denaturation step at 
95°C for 3 min followed by 35 cycles of: 95°C for 30 sec, primer specific annealing 
temperature for 30 sec, and 72°C for 45 sec extension, with a final extension at 72°C 




Quantitative real-time PCR (qRT-PCR) was performed using the iCycler 
apparatus (BioRad Inc., Hercules, CA) and mRNA presence was detected with the 
fluorochrome SYBR Green (IQ SYBR Green Supermix, BioRad Inc.).  All qRT-PCR 
reactions were performed in a 20 µL reaction volume using 500 nM of each specific 
primer.  Primer sequences used for bovine qRT-PCR reactions are shown in 
Appendix Table 6, and murine sequences are shown in Appendix Table 7.  Equivalent 
amounts of cDNA were used as templates for qRT-PCR.  Reactions were performed 
in triplicate for each sample.  The PCR program consisted of an initial denaturation 
step at 95°C for 3 minutes to activate the polymerase, followed by 40 cycles of: 
denaturation at 95°C for 30 seconds, specific annealing of each primer pair for 30 
seconds, and extension for 30 seconds at 72°C at which time fluorescence was 
measured.    
 
Statistical Analysis 
Transcription factor expression was recorded as present or absent in groups of 
bovine embryos analyzed at each stage of development.  Results were analyzed using 
a generalized linear mixed model in SAS version 9.0 (SAS institute, Cary, NC) with a 
binomial distribution. 
 
Percentage of embryo cleavage and development to blastocysts after injection 
of siRNA were recorded.  Frequencies of cleavage between treatments were analyzed 




Ct values from quantitative real-time PCR were normalized to β-Actin and the 
control treatment, standardized to 100, using the ∆∆ct method.  Statistical analysis was 
performed with SAS version 9.0 (SAS institute, Cary, NC).  Data are presented as 
means ± standard error of the mean (SEM).  Data were analyzed by one-way analysis 
of variance (ANOVA) with variance component estimated by treatment due to 
nonhomogeneous variances in samples.  Treatments within a graph denoted with 
different letters were significantly different (P<0.05).   
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Chapter 3: Evaluation of Lef1 in mammalian pre-
implantation embryos 
Introduction 
In mammals the network of transcription factors involved in cell fate and 
lineage differentiation of preimplantation embryos is critical for normal embryo 
development and implantation.  The differentiation of cells into either the inner cell 
mass (ICM) or trophectoderm (TE) at the end of the morula stage is the first 
segregation of cells into different fates.  The cells of the ICM are the progenitor cells 
of the three germ layers that eventually become the embryo proper, whereas the TE 
cells become placental tissues.  Knowing that proper differentiation of cells into the 
ICM and TE is critical for embryo development, the question to ask is which 
transcription factors are influencing this push into different cell types at this stage.  In 
addition to the well characterized Oct4, Nanog, and Cdx2, our laboratory has found 
another transcription factor, known as Lef1, which has different isoforms expressed 
in early development.  In preliminary work conducted in our laboratory using mouse 
ES cells and early embryos, we found a full-length Lef1 isoform being expressed in 
adult tissues and mouse embryonic fibroblasts (MEF), but it was nearly undetectable 
in the more pluripotent cells of morulae and blastocysts.  On the other hand, Lef1∆6 , 
which lacks the sixth exon, was seen at the morula and blastocyst stages in mouse 
embryos and down-regulated in MEF and adult tissues.  The expression of different 
isoforms in early development implies Lef1 could be involved in this network of 





Other studies in our laboratory, using mouse ES cells, indicate that Lef1 may 
be involved in early TE lineage determination.  In this study, we wanted to determine 
if Lef1was involved in cell fate determination of preimplantation embryos.  Since 
failure of proper TE development is one of the major causes of early gestational loss 
in cattle following embryo transfer (ET) of manipulated embryos, we chose to look at 
the role of Lef1 in bovine embryos.  In addition to bovine embryos, mouse embryos 
were used as a basis to understand Lef1 function since mouse strains have been well 
characterized and offer a relatively uniform population of embryos with high 
blastocysts rates.  Furthermore, as we were interested in the period in which murine 
and bovine development begins to diverge, we needed to assess expression in both 
bovine and murine embryos in order to gain a better understanding of the function 
and expression patterns of Lef1 during this critical phase.   
 
  First we wanted to determine the normal expression pattern of Lef1 and other 
key transcription factors at different stages in bovine pre-implantation embryo 
development.  Because many other studies have been conducted to determine 
expression of pluripotent markers in murine embryos, we can compare the expression 
pattern of transcription factors in these two mammalian species.  Second, we wanted 
to determine the role that Lef1 plays in early embryo development.  To accomplish 
this, we have chosen to use siRNA against the Lef1 gene.  This approach allows for a 





Expression of early differentiation transcription factors in bovine embryos 
Pools of bovine embryos collected at different stages were assayed to 
determine if Oct4, Nanog, Cdx2, and Lef1 mRNAs were present (Table 1).  Our 
results show that Oct4 was present in all preimplantation embryo stages collected.  
All three replicates indicated Oct4 was expressed throughout preimplantation embryo 
development from oocytes through blastocysts.   In oocytes, Nanog and Cdx2 
mRNAs were not present in any of the embryo pools tested, but both isoforms of Lef1 
were expressed.  Similar results were found in the 2-cell embryos collected.  In one of 
the three pools of 2-cell embryos, however, the full-length Lef1 was not present, as 
indicated by the 66% “+/-.”  By the 4- to 8-cell stage some embryos were positive for 
Nanog and Cdx2, but most did not express Nanog or Cdx2 at this stage.  The amount 
of full- length Lef1 isoform appeared to decrease by this time, whereas most of the 4-
8 cell embryos were still positive for the ∆6 isoform.  Pools of morulae collected 
indicated a mixed population of embryos.  Most of the morulae were still not 
expressing Nanog, and the Lef1∆6 isoform appeared to be the dominate form of Lef1 
at this stage.  Cdx2 expression shifted and was present in most morulae tested.  By the 
blastocyst stage there was an inconsistent expression of Nanog, Cdx2, and both Lef1 
isoforms; one pooled population of embryos was positive, while another was not.  
Looking specifically at Lef1 (Figure 3), the Lef1∆6 isoform was dominant in the early 
embryo where the cells were more pluripotent.  Both isoforms were present in 2-cell 
embryos, but it was clear that the ∆6 form was expressed at higher levels.  At 4- to 8-
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cell, morulae, and blastocyst stages only the ∆6 isoform was present, and it appeared 
that as the embryo develops, expression of this isoform was decreasing.  In bovine 
cell lines and oocytes, both isoforms were present.  In the cell lines there was no 
apparent difference in expression between the isoforms, but oocytes clearly had more 
Lef1∆6 present. 
 
Validation of Lef1 siRNA in bovine fetal fibroblasts 
 To ensure that the siRNA specifically designed to decrease expression of 
bovine Lef1 was functioning properly, Lef1 siRNA oligonucleotides and non-specific 
missense siRNA oligonucleotides were transfected into bovine fetal fibroblasts.  
Results from quantitative real-time PCR indicated that the Lef1 siRNA decreased 
Lef1 expression in these cells (Figure 4).  Lef1 siRNA-transfected cells were 
statistically different from both control cells in which no siRNA was added to the 
cells (P=0.0035) and from the missense siRNA transfected cells (P=0.0010).  The 
missense transfected cells and control cells were not statistically different (P=0.08).   
 
The expression of Cdx2 in these cells was also significantly decreased when 
the Lef1 siRNA was used.  In fact, there was a significant difference between all of 
the treatments analyzed.  The cells treated with Lef1 siRNA had a lower Cdx2 
expression than both the missense treated cells (P=0.0308) and untreated control cells 
(P<0.0001).  Also, there was a significant difference between the control and 
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missense siRNA transfected cells (P=0.0002) which may be indicating an off-target 
effect on Cdx2 in the missense siRNA treatments. 
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Microinjection of siRNA into bovine embryos 
Once the Lef1 siRNA was validated, we had to determine the best way to 
deliver the siRNA into embryos.  Because the development of in vitro derived 
embryos depends on the environment and how the embryos are handled, a non 
invasive direct incubation of the embryos with high concentrations of siRNA was 
attempted first (Kawamura et al., 2003).  Unfortunately, the embryos did not survive 
a 22-hour incubation with the siRNA (Appendix Figure 4).   The increased 
concentration of EDTA in the commercially designed siRNA buffer probably had 
detrimental effects on the embryos.  Therefore, an alternative approach using 
microinjection was used.  Lef1 or missense siRNA were injected into the cytoplasm 
of 1-cell bovine embryos.  A FemtoJet was used to provide a more consistent volume 
of injection.  The siRNA was mixed with Neutral Conjugated Texas Red Dextran 
(TRD) to visualize the amount being ejected from the microinjection needle.  After a 
successful injection of the siRNA-TRD, TRD was seen in the cytoplasm (Figure 5).  
TRD could also be seen in the perivitelline space of the embryos, which was caused 
by leakage from the needle during the injection process.  Embryo survivability, as 
determined by cleavage after injection, was observed the next day (44-48 hours post 
fertilization).  An average of 41.2 ± 2.3% of the embryos had cleaved (Table 2).  
Although the survivability rate of the injected embryos was low (41.2 ± 2.3%), the 
control group also only had 42.4% of embryo cleaved by this time (Table 2).  No 
morphological differences were seen between the three treatment groups of bovine 
embryos (Figure 6).  At this time all dead embryos were removed.  The following day 
when the embryos were at the 4- to 8-cell stage, groups of approximately 20 embryos 
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were pooled together and placed in lysis buffer for extraction of total RNA.  The 
remaining embryos were kept in culture until day 7 after fertilization when 
blastocysts should have been formed.  Unfortunately, no bovine blastocysts were 
present in any of the three treatment groups so no bovine blastocysts could be 
collected for analysis.   
 
Quantitative real-time PCR was used to determine the expression of Lef1 and 
Oct4 mRNA in early bovine embryos after the injection of siRNA:  Both TFs were 
shown to be expressed in bovine 4-8 cell embryos (Figure 7).  As expected, Lef1 was 
significantly decreased in bovine embryos; expression was decreased by about 90%.  
There was no significant difference in Oct4 mRNA expression in any of the three 
treatment groups in the 4-8 cell embryos.  Levels of Nanog and Cdx2 mRNAs were 
not analyzed in the bovine 4-8 cell embryos because RT-PCR results indicated neither 
factor was expressed at that stage in development.  A summary of the qRT-PCR data 
from both bovine fetal fibroblasts cells and injected bovine embryos can be found in 
Figure 8. 
 
Validation of Lef1 siRNA in mouse ES cells 
Although no bovine blastocysts developed, we were able to use mouse 
embryos to examine at the role of Lef1 in early blastocyst differentiation.  Before the 
murine specific Lef1 siRNA could be injected into embryos, the expected knockdown 
of Lef1 needed to be validated in mouse cell lines.  The murine Lef1 siRNA and 
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missense siRNA were transiently transfected into mouse ES cells.  Once again the 
Lef1 siRNA appeared to be decreasing the expression of Lef1 mRNA in cells by 
roughly 60%, and there was no significant difference between the control treatment 
and those cells treated with missense siRNA (Figure 9).   
 
 In mouse ES cells the addition of Lef1 siRNA did not affect the expression of 
Cdx2; all treatments were not statistically different (Figure 9).  Both Nanog and Oct4 
mRNA expression were increased by about 40% in the mouse cell lines, but only the 
expression of Nanog was significantly different (P=0.0178) from the control group.  
However, it must be pointed out that although the control and siRNA groups were 
different there was no difference in Nanog expression between the missense and Lef1 
siRNA transfected cells.  The expression of Oct4 increased after Lef1 siRNA 
transfection, but it was not statistically different from the missense or control groups. 
 
Microinjection of siRNA into mouse embryos 
After the validation of the mouse specific Lef1 siRNA in mouse ES cells, the 
Lef1 and missense siRNA were injected into the cytoplasm of thawed 1-cell murine 
embryos.  The same microinjection techniques were used in both bovine and murine 
embryos.  When embryo survivability after injection was observed the next day, 
cleavage had occurred in 58.6% of the embryos injected with missense siRNA and 
75.4% in embryos injected with the Lef1 siRNA (Table 3).  In the control embryos, 
95.9% had divided into at least 2-cells 24-hours after being thawed (Table 3).  There 
 36 
 
was a significant difference (P<0.01) in frequency of cleavage between all injected 
treatments.  The following day, when the embryos had cleaved into 4-8 cells, groups 
of approximately 20 embryos were pooled together and placed in lysis buffer for 
extraction of total RNA.  The remaining embryos were kept in culture until day 3.5 
after thawing when blastocysts should have been formed.  In all three groups about 
half of the remaining embryos had developed into blastocysts. 
 
Quantitative real-time PCR was used to determine the expression of Lef1, 
Cdx2, and Oct4 mRNA in early mouse embryos after the injection of siRNA.  Either 
missense siRNA or Lef1 siRNA was injected into embryos.  Levels of Lef1 mRNA 
could not be detected in most of the missense siRNA samples using qRT-PCR.  
Therefore, only the control and Lef1 siRNA treatments were shown (Figure 10).  
Results revealed that Lef1 expression was significantly (P=0.0345) decreased in 
embryos injected with Lef1 siRNA when compared to the non-injected control 
embryos.  Cdx2 expression was decreased by about 70% (P=0.0050) from the control 
group and by 15% (P=0.0224) from the missense group following injection with the 
Lef1 siRNA.  Oct4 was decreased by approximately 50% from the control 
(P=0.0241), but only about 20% from the missense siRNA treatment making it 
statistically not significant (P=0.1794).  Other missense and Lef1 siRNA groups were 
not statistically different.   
 
The murine blastocysts that developed from each of the three groups had no 
major morphological differences; all had a defined inner cell mass (ICM) and 
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trophectoderm (TE) layer (Figure 11).  However, in the embryos injected with Lef1 
siRNA, cells of the ICM did not appear as compact as those of the missense and 
control groups.  To better understand the consequence of decreasing Lef1 expression 
in a molecular-context, RNA was collected from the blastocysts and qRT-PCR was 
used to analyze changes in mRNA expression (Figure 12).  Results showed Lef1 
expression was significantly decreased from the control (P=0.0038) after injection of 
the Lef1 siRNA, but it was not statistically different from the missense injected 
siRNA, although there was a trend (P=0.0693).  There was also a significant decrease 
in Nanog (P=0.0358) and Oct4 (P=0.0088) mRNA expression when compared to the 
control treatment, but there was no significant difference (Nanog P=0.5161; Oct4 
P=0.3502) when compared with the missense siRNA injected embryos.  There was no 
significant difference in Cdx2 expression between any of the treatment groups. 
  
To ensure Lef1 depletion was not being compensated by one of the other three 
Tcf/Lef1 family members, the expression of these transcription factors was also 
tested.  The results indicated there was no significant difference between the control 
and siRNA or missense injected embryos in any of the other Tcf family members 
tested (Figure 13).  A summary of the qRT-PCR data from both mouse ES cells and 
injected murine embryos can be found in Figure 14. 
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Chapter 4:  Discussion 
 
 Our studies show that different isoforms of Lef1 are being expressed in early 
bovine and murine embryos, and that we can knockdown mRNA for this transcription 
factor using siRNA.  However, the injection of Lef1 siRNA into bovine and murine 
embryos did not provide any conclusive results as to the role that Lef1 plays in early 
embryo development.     
 
In the first experiments, we determined the expression of Oct4, Nanog, Cdx2, 
and Lef1 in bovine embryos to obtain an indication of when each transcription factor 
was active in early development.  Results showed Oct4 was present in bovine 
unfertilized oocytes and embryos through the blastocyst stage.  This pattern of 
expression was very similar to what has been seen in mouse early embryos; Oct4 was 
also found throughout early murine development (Boiani et al., 2002; Nichols et al., 
1998; Schöler et al., 1990).  Since Oct4 was present in 2-cell embryos it must be one 
of the stored maternal mRNAs found in oocytes because the embryonic genome is not 
yet active at this stage of development.  Our findings support data from the mouse 
that indicate Oct4 is needed early in development for normal blastocyst formation. 
 
Both Nanog and Cdx2 are expressed in murine embryos at the late morula and 
blastocyst stages as the cells of the embryo are beginning to diverge into different 
lineages (Beck et al., 1995; Chambers et al., 2003).  A similar pattern of expression is 
also seen in early bovine pre-implantation embryos.  Both Nanog and Cdx2 are not 
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expressed in oocytes and at the 2-cell stage, but by the 4-8 cell stage some embryos 
were positive for Nanog and Cdx2 mRNA expression.  Perhaps these findings were 
due to mRNA expression in some of the more advanced 8-cell embryos.  In sets of 
pooled morulae and blastocyts at least half of the pools express Nanog and Cdx2.            
 
The expression of Lef1 in early mouse and bovine embryos was dramatically 
different.  In bovine oocytes and 2-cell embryos, where the maternal stores of mRNA 
are present, both isoforms are expressed.  By the maternal zygotic transition (MZT) 
only the ∆6 isoform is present in the bovine embryos.  As the embryo develops, 
expression of this isoform appears to decrease with each cellular division.  This 
pattern is not seen in mouse early embryos, where there is a switch from full-length 
Lef1 expression at the 8-cell stage to Lef1∆6.  In murine morulae and blastocysts both 
isoforms are expressed, although the ∆6 isoform is dominant (He, unpublished).  
These results seem to indicate Lef1, particularly the ∆6 isoform, is another 
transcription factor involved in the lineage specification of cells in early embryos; 
altered isoform expression coincides with lineage divergence of cells.   
 
When we looked at the normal expression of Oct4, Nanog, Cdx2, and Lef1 in 
preimplantation bovine embryos, there was variation in the pools of embryos 
collected.  Because the oocytes were obtained from slaughterhouse animals that have 
very diverse genetic and management backgrounds it is not surprising that we see 
such variability.  Other studies conducted in our laboratory with the same type of 
bovine embryos have also shown a great deal of variance in transcription factor 
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expression from embryo to embryo.  This study points to embryo quality as a 
contributing factor for variability in transcription factor expression.  Also, there is a 
transition around the 8-cell stage in bovine embryos.  This transition is known as the 
maternal zygotic transition or MZT (Vigneault et al., 2004), and may be another 
reason why we saw variation of mRNA expression in embryos collected at this stage.   
 
In the second set of experiments completed, we used cell lines to validate how 
effectively Lef1 siRNA knocked down expression of total Lef1 mRNA.  The results 
indicated that the respective Lef1 siRNAs were effectively decreasing Lef1 mRNA 
expression in both bovine fetal fibroblasts and mouse ES cells.  However, we also 
observed a decrease in Cdx2 expression in the bovine fetal fibroblasts transfected 
with the missense siRNA.  Since the missense siRNA is a scrambled sequence of 
RNA with no known mRNA target, the decrease in Cdx2 expression was unexpected.  
When the bovine and murine missense siRNA sequences were compared against all 
known mRNA sequences in the bovine and murine genome there were no significant 
matches to any particular genes.  The decrease in Cdx2 after missense siRNA 
transfection may be due to off-target effects that are affecting the expression of Cdx2. 
These off-target effects may be from partial complementation of the missense siRNA 
to Cdx2 or another target upstream of Cdx2 that is strong enough to cause 
degradation the mRNA by the RISC complex or decreased transcription.  Regardless, 
the expression of Cdx2 in cells transfected with Lef1 siRNA was significantly 
different from both the control and missense transfected cells.  From this experiment 
it appears that decreasing total Lef1 mRNA in bovine fetal fibroblast also decreases 
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Cdx2 expression, providing further evidence for a connection between Cdx2 and 
Lef1.    
 
In our final experiments, Lef1 and missense siRNA were injected into bovine 
and murine embryos to determine the role of Lef1 in early embryo development.  In 
the 4-8 cell embryos collected, there was a decrease in Lef1 mRNA after the embryos 
were injected with the Lef1 siRNA, indicating microinjection is an effective method 
of siRNA delivery into embryos.  Unfortunately, in the bovine embryos no 
blastocysts developed, even in the non-injected control group of embryos.  Since the 
lack of blastocyst development cannot be attributed to a decrease in Lef1 expression, 
it is probably due to the quality of embryos collected.  As with the embryos used in 
the expression study, these embryos were from slaughterhouse animals with variable 
genetic and management backgrounds.  Even though the fetal fibroblasts indicated a 
possible link between Cdx2 and Lef1 in the bovine, we cannot examine this 
relationship in early embryos because no bovine blastocysts development.  At this 
time, we cannot make any claims about the role that Lef1 plays in early bovine 
embryos.  
 
To overcome the issue with embryo quality, mouse embryos were used.  
These commercially purchased embryos have a 90% blastocyst development rate so 
any effect seen should not be due to poor embryo quality.  In the 4-8 cell embryos, 
Lef1 expression in embryos injected with missense siRNA were unable to be 
analyzed accurately, because several data points were undetectable by qRT-PCR for 
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unknown reasons.  Even though the missense treatment was not used, we still 
determined that Lef1 expression appeared to decrease in murine embryos injected 
with Lef1 siRNA.  In the other two genes examined at this stage, the missense siRNA 
appeared to have significantly decreased expression when compared to the control 
embryos.  This should not be because of off-target effects since none were seen in 
mouse ES cells.  Instead, micromanipulation of the embryos was probably the cause 
of the observed significant difference between the control and missense siRNA 
treatments.  To better understand why we are seeing this difference, another control 
treatment of injected siRNA buffer and TRD would be needed to help determine if 
the decrease in expression at this stage was caused by the microinjection process 
rather than a poorly designed missense siRNA.  As in the bovine fetal fibroblasts, we 
also see a decrease at the 4-8 cells stage in Cdx2 expression after the embryos were 
injected with the Lef1 siRNA when compared to both the control and the missense 
injected embryos.  However, this effect does not continue in the murine blastocyts 
sampled.  Previous work in our laboratory has shown a connection between Lef1 and 
Cdx2 expression in mouse ES cells, but only when Wnt3a, an agonist of the Wnt 
pathway, was also added to the cells (He, unpublished).  Even though it appears that a 
decrease in Lef1 mRNA affected Cdx2 expression, further studies that also look at the 
role of Wnt3a need to be conducted before we can determine how these factors are 
interacting.     
 
One might expect that if Lef1 is involved in TE differentiation, a more 
pluripotent population of cells expressing higher levels of Nanog and Oct4 would be 
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seen following Lef1 mRNA knock-down in blastocysts.  This, however, is not what 
we see in the murine embryos.  There was no change in Nanog and Oct4 expression 
in embryos injected with Lef1 siRNA when compared to the missense injected 
embryos.  In addition, we did not see a difference in Cdx2 expression in any of the 
treatments.  Since the missense treatment did not affect mRNA levels in mESC, it is 
likely that the injection process was altering mRNA levels. Therefore, we assumed 
that the missense siRNA treatment was the better control for comparison of changes 
in mRNA expression.   We would need to add another treatment group of embryos 
that are injected with TRD and siRNA buffer, but no siRNA, to ensure there are no 
off-target effects in embryos from the missense siRNA. 
 
Other Tcf/Lef1 family members were also analyzed to determine if another 
closely related family member was upregulated to compensate for the decreased Lef1 
in the early embryos.  There were no significant changes in expression of the family 
members in any of the treatment groups.  It is possible that even though blastocysts 
form, the alteration of Lef1 expression could affect the ability of the embryo to 
implant into the uterus.  It would be interesting to test whether blastocyts from each 




Chapter 5: Conclusions 
Summary 
 Although a definitive role of Lef1 in early embryo development was not 
identified in this study, we were able to determine the expression pattern of Lef1 and 
other transcription factors during bovine preimplantation development.  Furthermore, 
we have demonstrated that embryos can survive microinjection of siRNA, although it 
appears that the injection process does have some detrimental effects on the embryos.  
To make more definitive conclusions, additional replicates of larger embryo pools 
would need to be tested.  This should decrease the large variation seen with some of 
the transcription factors tested.  Also, the use of qRT-PCR to detect minute quantities 
of transcription factors from such a small number of cells may be near or below the 
limitations of the system.  Until there is a consistent method that is sensitive enough 
to detect changes in such small amounts of mRNA, larger pools of embryos will be 
required.   
 
Future Studies 
 Our studies show a decrease in Cdx2 expression when Lef1 mRNA is 
knocked down in the bovine fetal fibroblasts.  Results from the mouse 4-8 cell 
embryos also suggest there is a relationship between Cdx2 and Lef1.  Recent work in 
our laboratory has shown that addition of the Wnt agonist Wnt3a in embryonic stem 
cells permits an increase of Lef1 mRNA to act synergistically to increase expression 
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of Cdx2 (He, unpublished).  These findings suggest that Wnt, Lef1, and Cdx2 are all 
interconnected.  It would be interesting to look at the change in Cdx2 and Lef1 
expression following stimulation of the Wnt pathway by Wnt3a in early murine 
embryos.  Results could reveal if Cdx2 and/or Lef1 are targets of the Wnt pathway in 
these early stages of embryo development.  Assuming that there is a relationship 
between the factors in murine embryos, experiments using siRNA against Lef1 and 
Cdx2 as well as antagonists of the Wnt pathway could be completed to determine 
mRNA expression with qRT-PCR and protein location and interactions using 
immunocytochemsitry and western blots.     
 
As we learned from this study, there is considerable variability in embryos 
produced using slaughterhouse-derived oocytes.  If we were to conduct additional 
experiments with bovine embryos, results should be more conclusive if larger 
numbers of embryos were analyzed and the embryos were obtained from cattle with 
similar genetic and management backgrounds such as the Wye Angus herd.       
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Table 1: Expression of early differentiation transcription factors at different 
stages in bovine embryos 
Summary of data from RT-PCR amplification of each transcription factor.  Three 
pools (n=20) of embryos at each stage were analyzed except at the blastocyst stage 
where only 2 pools (n=9 or 10) were obtained.  A minus “-” indicates mRNA was not 
detected, a plus “+” indicates mRNA expression was seen, and a plus-minus “+/-” 
indicates a different results were obtained from one group of embryos to the next.  
Numbers below denote the percentage of embryo pools that were positive for 
transcription factor expression.   
 























































Figure 3: Expression of Lef1 in early bovine embryos and cell lines 
Lef1 mRNA expression patterns in bovine pre-implantation embryos, bovine cumulus 
cell lines, and bovine fetal fibroblasts.  A white band indicates Lef1 mRNA is being 
expressed at the embryo stage identified.  Upper bands are representative of full-





Figure 4: Validation of bovine Lef1 siRNA in bovine fetal fibroblasts  
Bovine fetal fibroblasts were transfected with Lef1 specific siRNA (white) or non-
specific missense siRNA (grey).  As a control, another group of cells were not 
transfected (black).  Quantitative real-time PCR was used to determine expression of 
Lef1 and Cdx2 in the fibroblasts.  Presented is the mean ± SEM of the change in Lef1 
or Cdx2 relative to β-Actin after transfection with missense or Lef1 siRNA.  Both 
treatments were normalized to β-Actin as well as an average of the control treatments.  






Figure 5: Bovine embryos after injection of siRNA-TRD 
Bovine 1-cell embryos were injected with approximately 10-20 pmol of Lef1 or 
missense siRNA, each were mixed with Texas Red Dextran (TRD).  The presence of 
TRD acts as a fluorescent marker indicating successful injection.  Below are a group 
of these embryos after injection.  Top panel (a) is a group of the bovine embryos 
viewed under a light-microscope at 20x magnification.  The middle panel (b) is the 
same group of embryos shown with fluorescence emission.  The bottom panel (c) 









Table 2: Bovine embryo cleavage rates after injection of Lef1 and missense 
siRNA 
Total number of embryos used for each treatment group, as well as, the number 
cleaved after 44-48 hours post fertilization (hpf).  The last column is percentages of 
embryos that were cleaved.  Treatments not significantly different were denoted by 
the same superscript letter. 
 
 





271 115 42.4%a 
Missense siRNA 
272 106 38.9%a 
Lef1 siRNA 






Figure 6: Bovine embryos after siRNA injections 
Bovine embryos 24 hours after siRNA injection.  The top group of embryos (a) 
represent the control treatment of embryos that were not injected.  In the middle (b) is 
a representative group of embryos that were injected with missense siRNA.  On the 






Figure 7: Bovine 4- to 8- cell staged bovine embryos after injection with Lef1 
siRNA 
 
Bovine 1-cell embryos were injected with Lef1 specific siRNA (white) or non-
specific missense siRNA (grey).  As a control another group of cells were given no 
treatment (black).  Embryos were collected at the 4-8 cell stage and total RNA was 
isolated.  Quantitative real-time PCR was used to determine expression of Lef1 and 
Oct4 in the embryos.  Presented results are the mean ± SEM of the change in Lef1 
and Oct4 relative to β-Actin after transfection with missense or Lef1 siRNA.  Both 
treatments were normalized to β-Actin and an average of the control treatments.  










Figure 8:  Summary of qRT-PCR data in the bovine 
The table below is a summary of the transcription factors analyzed after transfection 
or injection of Lef1 siRNA in the different bovine cells collected.  A “↓” indicates 
mRNA expression is significantly decreased after addition of the Lef1 siRNA when 
compared to the control specified above.  A “↔” indicates no statistical different in 
mRNA expression when compared to the control specified above.  The “N/A” 
indicates that particular transcription factor was not analyzed because the mRNA was 
not expressed in the cells collected. 
 
 
Bovine Fetal fibroblasts 4-8 cell embryos 
 Change Relative to 
Control 
Change Relative to 
Missense Control 
Change Relative to 
Missense Control 
Lef1 ↓ ↓ ↓ 
Cdx2 ↓ ↓ N/A 
Nanog N/A N/A N/A 






Figure 9: Validation of murine specific Lef1 siRNA in mouse ES cells 
Mouse ES cells were transfected with Lef1 specific siRNA (white) or non-specific 
missense siRNA (grey).  As a control another group of cells were not transfected with 
either siRNA (black).  Cells were collected 24-hours after transfection and total RNA 
was isolated.  Quantitative real-time PCR was used to determine expression of Lef1, 
Cdx2, Nanog and Oct4 in these cells.  Presented results are the mean ± SEM of the 
change in Lef1, Cdx2, Nanog, and Oct4 expression relative to β-Actin after 
transfection with missense or Lef1 siRNA.  Both treatments were normalized to β-
Actin and an average of the control treatments.  Different letters within a gene 








Table 3: Murine embryo cleavage rates after injection of siRNA 
Below is a table indicating the total number of embryos used for each treatment group 
of injected embryos, as well as, the number of embryos cleaved the day after 
injections.  Embryos that were lysed before cleaving into 2-cells were removed from 
the experiment and not taken into consideration for blastocyst rate.  Also 
approximately 20 embryos from each treatment were removed at the 4-8 cell stage for 
processing.  Different letters within column indicate treatments are significantly 
different at P<0.01. 
 
 





139 134 96.4%a 70%a 
Missense siRNA 
183 106 57.9%c 48.5%b 
Lef1 siRNA 




Figure 10: Mouse 4-8 cell embryos after Lef1 siRNA injection 
Mouse 1-cell embryos were injected with Lef1 specific siRNA (white) or non-
specific missense siRNA (grey).  As a control another group of cells were given no 
treatment (black).  4-8 cell embryos were collected 48-hours after injection and total 
RNA was isolated.  Quantitative real-time PCR was used to determine expression of 
Lef1, Cdx2, and Oct4 in these cells.  Presented results are the mean ± SEM of the 
change in Lef1, Cdx2, and Oct4 relative to β-Actin after transfection with missense or 
Lef1 siRNA.  Both treatments were normalized to β-Actin an average of the control 
treatments.  Different letters within a gene indicate treatments are statistically 







Figure 11: Murine blastocyst morphology after siRNA injection 
Embryos below are murine Day 4 blastocysts at 40x magnification.  The embryo 
indicated by an “a” is from the control group in which no treatment was added.  The 
“b” indicates an embryo from the missense group where missense siRNA was 
injected at the 1-cell stage.  The “c” shows a representative from the Lef1 group that 





Figure 12: mRNA expression of key transcription factors in mouse blastocysts 
after siRNA injection 
Mouse 1-cell embryos were injected with Lef1 specific siRNA (white) or non-
specific missense siRNA (grey).  As a control another group of cells were given no 
treatment (black).  Blastocysts were collected 3.5 days after injection and total RNA 
was isolated.  Quantitative real-time PCR was used to determine expression of Lef1, 
Cdx2, Nanog and Oct4 in these cells.  Presented results are the mean ± SEM of the 
change in Lef1, Cdx2, Nanog, and Oct4 relative to β-Actin after transfection with 
missense or Lef1 siRNA.  Both treatments were normalized to β-Actin and the 
average of the control treatments.  Different letters within a gene indicate treatments 







Figure 13: Expression of Tcf/Lef family members in mouse blastocysts after Lef1 
siRNA injection 
Mouse 1-cell embryos were injected with Lef1 specific siRNA (white) or non-
specific missense siRNA (grey).  As a control another group of cells were given no 
treatment (black).  Blastocysts were collected 3.5 days after injection and total RNA 
was isolated.  Quantitative real-time PCR was used to determine expression of Tcf3 
and Tcf4 in these cells.  Presented results are the mean ± SEM of the change in Tcf3 
and Tcf4 expression relative to β-Actin after transfection with missense or Lef1 
siRNA.  Both treatments were normalized to β-Actin and the average of the control 
treatments.  Different letters within a gene indicate treatments are statistically 







Figure 14: Summary of qRT-PCR data in the mouse 
 
The table below is a summary of the transcription factors analyzed after transfection 
or injection of Lef1 siRNA in the different murine cells collected.  A “↓” indicates 
mRNA expression was significantly decreased after addition of the Lef1 siRNA when 
compared to the control specified above.  A “↔” indicates no statistical difference in 
mRNA expression when compared to the control specified above.  The “N/A” 
indicates that particular transcription factor was not analyzed because the mRNA was 
not expressed in the cells collected.  The star “*” denotes changes in expression were 
compared to the untreated control group because the missense control could not be 








Change Relative to 
Missense Control 
Change Relative to 
Missense Control 
Change Relative to 
Missense Control 
Lef1 ↓ ↓ ↓* ↔ 
Cdx2 ↔ ↔ ↓ ↔ 
Nanog ↑ ↔ N/A ↔ 
Oct4 ↔ ↔ ↔ ↔ 
Tcf3 N/A N/A N/A ↔ 





Appendix Table 1: Numbers of bovine embryos collected to determine gene 
expression at different early development stages 
 
 Oocyte 2-cell 4-8 cell Morula Blastocyst
Rep 1 20 20 20 20 9 
Rep 2 20 20 20 20 - 





Appendix Table 2: Numbers of bovine 4-8 cell embryos collected after siRNA 
injection  
 
 Control Lef1 siRNA Missense siRNA 
Rep 1 18 20 17 
Rep 2 20 14 17 
Rep 3 20 18 20 





Appendix Table 3: Numbers of murine 4-8 cell embryos collected after siRNA 
injection 
 
 Control Lef1 siRNA Missense siRNA 
Rep 1 20 20 20 
Rep 2 20 20 20 




Appendix Table 4: Numbers of murine blastocysts collected after siRNA 
injection  
 
 Control Lef1 siRNA Missense siRNA 
Rep 1 15 10 3 
Rep 2 6 9 5 
Rep 3 11 7 9 




Appendix Table 5: Bovine RT-PCR primer sequences 
 
Primer 







β-Actin TTGCTGACAGGATGCAGAAG 56 147 
 TGATCCACATCTGCTGGAAG   
    
Cdx2 AGTGAAAACCAGGACGAAAGACA 60 142 
 CTCTGAGAGCCCCAGCGT   
    
Lef1 GACGAGATGATCCCCTTCAA 56 760 &  
 TTAGGTCGCTGTCAGTGTGG  670 
    
Nanog GGAACTGCTGGGGAAAATTA 57 119 
 TACAAATCTTCAGGCTGTATGTTG   
    
Oct4 AGGAGTCCCAGGACATCAA 56 201 





Appendix Table 6: Bovine qRT-PCR primer sequences 
 
Primer 







β-Actin TTGCTGACAGGATGCAGAAG 56 147
 TGATCCACATCTGCTGGAAG  
   
Cdx2 AGTGAAAACCAGGACGAAAGACA 60 142
 CTCTGAGAGCCCCAGCGT  
   
Lef1 GACGAGATGATCCCCTTCAA 55 97
 TGTCGGCTAAGTCACCTTCC  
   
Nanog GGAACTGCTGGGGAAAATTA 57 119
 TACAAATCTTCAGGCTGTATGTTG   
    
Oct4 AGGAGTCCCAGGACATCAA 56 201





Appendix Table 7: Mouse qRT-PCR primer sequences 
 
Primer 
Sequence of forward and 






β-Actin TTGCTGACAGGATGCAGAAG 56 147
 TGATCCACATCTGCTGGAAG  
   
Cdx2 AGTGATTCCTGGGGCTTCTT 59 278
 TGCCTCTGGCTCCTGTAGTT  
   
Lef1 
Total  TGAAGCCTCAACACGAACAG 64 122
 CGTGCACTCAGCTACGACAT  
   
Nanog CTCCAGAAGAGGGCGTCAGA 61 285
 CCTTTGGTCCCAGCATTCAG   
    
Oct4 CCCGGAAGAGAAAGCGAACT 61 289
 ATAGCCTGGGGTGCCAAAGT  
 
Tcf1 GCGAGGAACAGGACGATAAG 55 ~100
 CCTCGGCTTCTCCATGTACT  
 
Tcf3 CTGTCGCTCACCACCAAAC 55 ~100
 GGAGCGTAGCTGGGAAAGTA  
 
Tcf4 GATGACCTAGGCGCTAACGA 55 ~100





Appendix Figure 1: Bovine Lef1 gene 






















Appendix Figure 2: Alignment of bovine, human, and mouse Lef1 genes 
The sequence alignment of the bovine, human, and mouse Lef1 mRNA.  A star 
indicates an exact match between the three sequences. 
 
bovine ATGCCCCAACTCTCCGGGGCAGGCGGCGGCGGTGGGGGGGACCCGGAACTCTGCGCCACG 60 
human  ATGCCCCAACTCTCCGGAGGAGGTGGCGGCGGCGGGGGGGACCCGGAACTCTGCGCCACG 60 
mouse  ATGCCCCAACTTTCCGGAGGAGGCGGCGG------GGGGGACCCGGAACTCTGCGCCACC 54 
       *********** ***** * *** *****      ************************  
bovine GACGAGATGATCCCCTTCAAGGACGAGGGCGATCCTCAGAAGGAGAAGATCTTCGCCGAG 120 
human  GACGAGATGATCCCCTTCAAGGACGAGGGCGATCCTCAGAAGGAAAAGATCTTCGCCGAG 120 
mouse  GATGAGATGATCCCCTTCAAGGACGAAGGCGATCCCCAGAAGGAGAAGATCTTCGCCGAG 114 
       ** *********************** ******** ******** *************** 
bovine ATCAGTCACCCTGAAGAGGAAGGTGACTTAGCCGACATCAAGTCTTCCTTGGTCAACGAA 180 
human  ATCAGTCATCCCGAAGAGGAAGGCGATTTAGCTGACATCAAGTCTTCCTTGGTGAACGAG 180 
mouse  ATCAGTCATCCCGAAGAGGAGGGCGACTTAGCCGACATCAAGTCATCTTTGGTTAACGAG 174 
       ******** ** ******** ** ** ***** *********** ** ***** *****  
bovine TCCGAAATCATCCCGGCGAGCAACGGACACGAGGTGGCCAGACAAGCACAAACCTCTCAG 240 
human  TCTGAAATCATCCCGGCCAGCAACGGACACGAGGTGGCCAGACAAGCACAAACCTCTCAG 240 
mouse  TCCGAAATCATCCCAGCCAGCAACGGGCATGAGGTGGTCAGACAAGCCCCGTCCTCTCAG 234 
       ** *********** ** ******** ** ******* ********* *   ******** 
bovine GAGTCCTACCATGACAAGGCCAGAGAACATCCTGATGATGGAAAGCATCCAGATGGAGGT 300 
human  GAGCCCTACCACGACAAGGCCAGAGAACACCCCGATGACGGAAAGCATCCAGATGGAGGC 300 
mouse  GAGCCCTACCACGACAAGGCCAGAGAACACCCTGATGAAGGAAAGCATCCAGACGGAGGC 294 
       *** ******* ***************** ** ***** ************** *****  
bovine CTCTACAATAAGGGACCCTCTTACTCGAGTTATTCTGGATACATAATGATGCCAAATATG 360 
human  CTCTACAACAAGGGACCCTCCTACTCGAGTTATTCCGGGTACATAATGATGCCAAATATG 360 
mouse  CTGTACAACAAGGGACCCTCCTACTCCAGTTACTCTGGCTACATAATGATGCCCAATATG 354 
       ** ***** *********** ***** ***** ** ** ************** ****** 
bovine AATAATGACCCATACATGTCAAATGGATCTCTTTCTCCACCCATCCCAAGAACATCAAAT 420 
human  AATAACGACCCATACATGTCAAATGGATCTCTTTCTCCACCCATCCCGAGAACATCAAAT 420 
mouse  AACAGCGACCCGTACATGTCAAATGGGTCCCTTTCTCCACCCATCCCGAGGACATCAAAT 414 
       ** *  ***** ************** ** ***************** ** ********* 
bovine AAAGTGCCCGTGGTGCAGCCATCCCACGCGGTCCATCCTCTCACCCCTCTCATCACGTAC 480 
human  AAAGTGCCCGTGGTGCAGCCATCCCATGCGGTCCATCCTCTCACCCCCCTCATCACTTAC 480 
mouse  AAAGTGCCCGTGGTGCAGCCCTCTCACGCGGTCCACCCGCTCACCCCCCTCATCACCTAC 474 
       ******************** ** ** ******** ** ******** ******** *** 
bovine AGCGACGAGCACTTTTCTCCAGGATCACACCCGTCACACATCCCATCAGATGTCAACTCC 540 
human  AGTGACGAGCACTTTTCTCCAGGATCACACCCGTCACACATCCCATCAGATGTCAACTCC 540 
mouse  AGCGACGAGCACTTTTCTCCGGGATCCCACCCGTCACACATCCCGTCAGATGTCAACTCC 534 
       ** ***************** ***** ***************** *************** 
bovine AAACAAGGCATGTCCAGACATCCTCCAGCTCCCGAGATCCCTACGTTTTATCCCCTGTCT 600 
human  AAACAAGGCATGTCCAGACATCCTCCAGCTCCTGATATCCCTACTTTTTATCCCTTGTCT 600 
mouse  AAGCAAGGCATGTCCAGACACCCTCCAGCTCCTGAAATCCCCACCTTCTACCCCCTGTCT 594 
       ** ***************** *********** ** ***** ** ** ** *** ***** 
bovine CCGGGTGGTGTTGGACAGATTACCCCACCTCTTGGCTGGCAAGGTCAGCCTGTGTATCCC 660 
human  CCGGGTGGTGTTGGACAGATCACCCCACCTCTTGGCTGGCAAGGTCAGCCTGTATATCCC 660 
mouse  CCGGGCGGCGTTGGACAGATCACCCCACCCATTGGCTGGCAAGGTCAGCCTGTTTATCCC 654 
       ***** ** *********** ********  ********************** ****** 
bovine ATCACGGGAGGCTTCAGGCAGCCCTACCCATCCTCACTGTCAGTCGACACTTCCATGTCC 720 
human  ATCACGGGTGGATTCAGGCAACCCTACCCATCCTCACTGTCAGTCGACACTTCCATGTCC 720 
mouse  ATCACGGGTGGATTCAGGCAACCCTACCCATCCTCACTGTCAGGCGACACTTCCATGTCC 714 






bovine AGGTTTTCTCATCATATGATTCCTGGTCCTCCCGGTCCCCACACAACTGGCATCCCTCAT 780 
human  AGGTTTTCCCATCATATGATTCCCGGTCCTCCTGGTCCCCACACAACTGGCATCCCTCAT 780 
mouse  AGGTTTTCCCATCATATGATTCCTGGTCCCCCTGGCCCCCACACAACTGGCATCCCTCAT 774 
       ******** ************** ***** ** ** ************************ 
bovine CCAGCCATTGTAACGCCTCAGGTCAAACAGGAACACCCCCACACTGACAGCGACCTAATG 840 
human  CCAGCTATTGTAACACCTCAGGTCAAACAGGAACATCCCCACACTGACAGTGACCTAATG 840 
mouse  CCAGCTATTGTAACACCTCAGGTCAAACAGGAGCACCCCCACACGGACAGTGACCTAATG 834 
       ***** ******** ***************** ** ******** ***** ********* 
bovine CACGTGAAGCCTCAGCATGAACAGAGAAAGGAGCAGGAGCCAAAAAGACCTCACATTAAA 900 
human  CACGTGAAGCCTCAGCATGAACAGAGAAAGGAGCAGGAGCCAAAAAGACCTCACATTAAG 900 
mouse  CACGTGAAGCCTCAACACGAACAGAGAAAGGAGCAGGAGCCCAAAAGACCTCATATTAAG 894 
       ************** ** *********************** *********** *****  
bovine AAGCCTCTGAATGCTTTTATGTTATACATGAAAGAAATGAGAGCGAATGTCGTAGCTGAG 960 
human  AAGCCTCTGAATGCTTTTATGTTATACATGAAAGAAATGAGAGCGAATGTCGTTGCTGAG 960 
mouse  AAGCCTCTGAATGCTTTCATGTTATATATGAAAGAAATGAGAGCGAATGTCGTAGCTGAG 954 
       ***************** ******** ************************** ****** 
bovine TGTACTCTAAAGGAAAGTGCAGCTATCAACCAGATTCTAGGCAGAAGGTGGCATGCCCTC 1020 
human  TGTACTCTAAAAGAAAGTGCAGCTATCAACCAGATTCTTGGCAGAAGGTGGCATGCCCTC 1020 
mouse  TGCACGCTAAAGGAGAGTGCAGCTATCAACCAGATCCTGGGCAGAAGATGGCACGCCCTC 1014 
       ** ** ***** ** ******************** ** ******** ***** ****** 
bovine TCTCGTGAAGAGCAGGCTAAATATTATGAATTAGCGCGGAAGGAAAGACAGCTACATATG 1080 
human  TCCCGTGAAGAGCAGGCTAAATATTATGAATTAGCACGGAAAGAAAGACAGCTACATATG 1080 
mouse  TCCCGGGAAGAGCAGGCCAAATACTATGAACTAGCACGGAAAGAGAGACAGCTACACATG 1074 
       ** ** *********** ***** ****** **** ***** ** *********** *** 
bovine CAGCTCTATCCAGGCTGGTCTGCAAGAGACAATTATGGTAAGAAAAAGAAGAGGAAGAGA 1140 
human  CAGCTTTATCCAGGCTGGTCTGCAAGAGACAATTATGGTAAGAAAAAGAAGAGGAAGAGA 1140 
mouse  CAGCTTTATCCAGGCTGGTCAGCGCGAGACAATTATGGCAAGAAGAAGAAGAGGAAGAGA 1134 
       ***** ************** **  ************* ***** *************** 
bovine GAGAAGCTACAGGAATCCACATCAGGTACAGGTCCAAGAATGACAGCTGCCTACATCTGA 1200 
human  GAGAAACTACAGGAATCTGCATCAGGTACAGGTCCAAGAATGACAGCTGCCTACATCTGA 1200 
mouse  GAGAAGCTACAGGAGTCGACTTCAGGTACAGGTCCCAGAATGACAGCTGCCTACATCTGA 1194 




Appendix Figure 3: Injection of siRNA into bovine embryo 
Below is a 40x magnification image of a bovine embryo being injected with siRNA-








Appendix Figure 4: Direct incubation pilot study 
Below are images of bovine embryos used in a pilot study to determine if bovine 
embryos could be cultured in 50 µM of siRNA and survive.  A-C are 4-cell embryos 
before the addition of siRNA to the 50 µL culture drop of G1 media.  D-E are the 
same embryos 22 hours after the addition of siRNA to the culture media.  Groups A 
and D are the control embryos where nothing was added to the media.  B and E had 
50 µM of non-specific missense siRNA added to the 50 µL drop.  C and F are the 
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